Status:
UNKNOWN
Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection
Lead Sponsor:
Hebei Medical University Fourth Hospital
Conditions:
Non-small Cell Lung Cancer Stage Ⅱ
Non-small Cell Lung Cancer Stage ⅢA
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate S1 capsule plus Cisplatin as adjuvant treatment in stageⅡ and Ⅲa non-small cell lung cancer. It is the first study in the world to investigate the safety and e...
Detailed Description
Lung cancer is the leading cause of cancer death worldwide. Only about 15.6% of all lung cancer patients are alive 5years or more after diagnosis. Non-small Cell Lung Cancer (NSCLC) accounts for more ...
Eligibility Criteria
Inclusion
- Patient with completely resected stage ⅢA non-small cell lung cancer(NSCLC)
- Must be able to receive the therapy of the study within four weeks after the completely resection
Exclusion
- Systemic anticancer treatment
- local radiotherapy
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02223611
Start Date
December 1 2014
End Date
December 1 2018
Last Update
August 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jun Feng Liu
Shijiazhuang, Hebei, China, 050011